Abenaa Brewster is an Oncology physician affiliated with The University of Texas MD Anderson Cancer Center. OpenAlex indexes 227 publications with 5,713 citations (h-index 38); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304009
Telephone
713-792-6161Registry record last updated 22 Dec 2009.
Clinical trials
- Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Sponsor: M.D. Anderson Cancer Center
- Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)
Sponsor: M.D. Anderson Cancer Center
- Preventing Sexual Dysfunction With Aromatase Inhibitors
Sponsor: M.D. Anderson Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ethicon US, LLCProgram year20251 payment
- Lilly USA, LLCProgram year20242 payments
- Ethicon US, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor44.2%Ibrance70%Verzenio30%Part D<11 patientsEstrogen Agonist/Antagonist28.3%Tamoxifen Citrate100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2006–2017 per NIH RePORTER. The latest:
- Risk Prediction for ER Negative Breast Cancer Recurrence
Baylor College of Medicine
FY2017$593,132R01CA172511 - Risk Prediction for ER Negative Breast Cancer Recurrence
Baylor College of Medicine
FY2016$614,362R01CA172511 - Risk Prediction for ER Negative Breast Cancer Recurrence
Baylor College of Medicine
FY2015$624,192R01CA172511
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Alcohol and Cancer: Existing Knowledge and Evidence Gaps across the Cancer Continuum
Cancer Epidemiology Biomarkers & Prevention
2021 - Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update
Journal of Clinical Oncology
2019
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”